Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization

This publication has 14 references indexed in Scilit:

• Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome?
  The Journal of Thoracic and Cardiovascular Surgery, 1996
• UTILIZATION OF INTRAVENOUS IMMUNOGLOBULIN TO AMELIORATE ALLOANTIBODIES IN A HIGHLY SENSITIZED PATIENT WITH A CARDIAC ASSIST DEVICE AWAITING HEART TRANSPLANTATION
  Transplantation, 1996
• Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices
  The Annals of Thoracic Surgery, 1995
• Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality
  The Annals of Thoracic Surgery, 1995
• SOLUBLE HLA CLASS II CONCENTRATIONS IN NORMAL INDIVIDUALS AND TRANSPLANT RECIPIENTS
  Transplantation, 1994
• SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIg)
  Transplantation, 1993
• The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation
  Transplant Immunology, 1993
• Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device
  The Annals of Thoracic Surgery, 1992
• NEW APPROACHES TO DONOR CROSSMATCHING AND SUCCESSFUL TRANSPLANTATION OF HIGHLY SENSITIZED PATIENTS1,2
  Transplantation, 1983
• Hyperacute Renal-Homograft Rejection in Man
  New England Journal of Medicine, 1968